About Pacira BioSciences, Inc.
https://www.pacira.comPacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States.
CEO
Frank D. Lee
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 189
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:8.01M
Value:$178.07M
BLACKROCK, INC.
Shares:7.34M
Value:$163.16M
VANGUARD GROUP INC
Shares:5.2M
Value:$115.59M
Summary
Showing Top 3 of 331
About Pacira BioSciences, Inc.
https://www.pacira.comPacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $179.52M ▼ | $138.88M ▲ | $5.43M ▲ | 3.03% ▲ | $0.12 ▲ | $34.37M ▲ |
| Q2-2025 | $181.1M ▲ | $131.73M ▼ | $-4.85M ▼ | -2.68% ▼ | $-0.11 ▼ | $29.24M ▼ |
| Q1-2025 | $168.92M ▼ | $132.63M ▲ | $4.81M ▼ | 2.85% ▼ | $0.1 ▼ | $33.61M ▼ |
| Q4-2024 | $187.25M ▲ | $122.66M ▼ | $16.04M ▲ | 8.57% ▲ | $0.35 ▲ | $50.6M ▲ |
| Q3-2024 | $168.57M | $269.24M | $-143.47M | -85.11% | $-3.11 | $-114.75M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $246.33M ▼ | $1.3B ▼ | $570.36M ▼ | $727.21M ▼ |
| Q2-2025 | $445.86M ▼ | $1.54B ▼ | $779.5M ▼ | $757.77M ▼ |
| Q1-2025 | $493.63M ▲ | $1.59B ▲ | $788.13M ▲ | $798.54M ▲ |
| Q4-2024 | $484.62M ▲ | $1.55B ▲ | $775.17M ▲ | $778.35M ▲ |
| Q3-2024 | $453.81M | $1.52B | $772.11M | $749.58M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $5.43M ▲ | $60.83M ▲ | $43.61M ▼ | $-257.48M ▼ | $-152.9M ▼ | $56.96M ▲ |
| Q2-2025 | $-4.85M ▼ | $12.01M ▼ | $62.16M ▲ | $-57.51M ▼ | $16.87M ▲ | $9.31M ▼ |
| Q1-2025 | $4.81M ▼ | $35.46M ▲ | $-25.63M ▼ | $-2.99M ▼ | $6.84M ▼ | $26.91M ▼ |
| Q4-2024 | $16.04M ▲ | $33.13M ▼ | $-368K ▲ | $-1.96M ▲ | $30.81M ▲ | $31.01M ▼ |
| Q3-2024 | $-143.47M | $53.92M | $-52.16M | $-2.85M | $-1.09M | $49.83M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Bupivacaine Liposome Injectable Suspension | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 EXPAREL | $150.00M ▲ | $140.00M ▼ | $140.00M ▲ | $140.00M ▲ |
 Product | $190.00M ▲ | $170.00M ▼ | $180.00M ▲ | $180.00M ▲ |
 ZILRETTA | $30.00M ▲ | $20.00M ▼ | $30.00M ▲ | $30.00M ▲ |
CEO
Frank D. Lee
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 189
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:8.01M
Value:$178.07M
BLACKROCK, INC.
Shares:7.34M
Value:$163.16M
VANGUARD GROUP INC
Shares:5.2M
Value:$115.59M
Summary
Showing Top 3 of 331